Abstract
Birth defects and other adverse outcomes of pregnancy have been known since before the industrial age, but the need for guidelines to test chemicals to which pregnant women might be exposed was defined by the thalidomide tragedy in the 1950s and early 1960s. During the five decades that followed the tragedy, guidelines were written to test drugs, foods, and environmental contaminants. The guidelines were written to fulfill national needs, and then were expanded to international levels in order to streamline procedures in the expanding global economy. Multiple sets of animal guidelines were written, based on the need to simulate human experience. It was soon realized that the underlying principles were similar for all guidelines. Guidelines gradually evolved in two directions, in complexity and number of endpoints measured and in the expansion of internationally acceptable guidelines. This manuscript reviews, in chronological order, some of the milestones in the development of guidelines for animal studies and in the interpretations for safety assessment. Guidelines for long-term and short-term studies are reviewed, followed by a discussion of recently added endpoints and the future integration process for the assessment of reproductive toxicity risk.
Keywords: teratology, reproduction, Guidelines
Current Pharmaceutical Design
Title: History and Evolution of Reproductive and Developmental Toxicology Guidelines
Volume: 12 Issue: 12
Author(s): Thomas F.X. Collins
Affiliation:
Keywords: teratology, reproduction, Guidelines
Abstract: Birth defects and other adverse outcomes of pregnancy have been known since before the industrial age, but the need for guidelines to test chemicals to which pregnant women might be exposed was defined by the thalidomide tragedy in the 1950s and early 1960s. During the five decades that followed the tragedy, guidelines were written to test drugs, foods, and environmental contaminants. The guidelines were written to fulfill national needs, and then were expanded to international levels in order to streamline procedures in the expanding global economy. Multiple sets of animal guidelines were written, based on the need to simulate human experience. It was soon realized that the underlying principles were similar for all guidelines. Guidelines gradually evolved in two directions, in complexity and number of endpoints measured and in the expansion of internationally acceptable guidelines. This manuscript reviews, in chronological order, some of the milestones in the development of guidelines for animal studies and in the interpretations for safety assessment. Guidelines for long-term and short-term studies are reviewed, followed by a discussion of recently added endpoints and the future integration process for the assessment of reproductive toxicity risk.
Export Options
About this article
Cite this article as:
Collins F.X. Thomas, History and Evolution of Reproductive and Developmental Toxicology Guidelines, Current Pharmaceutical Design 2006; 12 (12) . https://dx.doi.org/10.2174/138161206776389813
DOI https://dx.doi.org/10.2174/138161206776389813 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Wide-Ranging Genomic Effects of Plasticisers and Related Compounds
Current Drug Metabolism Association Between Total Bilirubin Levels and Cardio-Metabolic Risk Factors Related to Obesity
Endocrine, Metabolic & Immune Disorders - Drug Targets Prevention of Upper Gastrointestinal Ulcer and Complications in Low-Dose Aspirin Users
Current Pharmaceutical Design Anticancer Potential of Dietary Natural Products: A Comprehensive Review
Anti-Cancer Agents in Medicinal Chemistry Applications of Nanosystems to Anticancer Drug Therapy (Part II. Dendrimers, Micelles, Lipid-based Nanosystems)
Recent Patents on Anti-Cancer Drug Discovery ‘From Death, Lead Me to Immortality’ – Mantra of Ageing Skeletal Muscle
Current Genomics Aberrant DNA Methylation and Prostate Cancer
Current Genomics The Urokinase Plasminogen Activator System: A Target for Anti-Cancer Therapy
Current Cancer Drug Targets Neuroprotective Properties of Erythropoietin in Cerebral Ischemia
Central Nervous System Agents in Medicinal Chemistry Understanding Abnormal c-JNK/p38MAPK Signaling in Amyotrophic Lateral Sclerosis: Potential Drug Targets and Influences on Neurological Disorders
CNS & Neurological Disorders - Drug Targets Approaches for Imaging the Diabetic Pancreas: First Results
Current Medicinal Chemistry - Immunology, Endocrine & Metabolic Agents Advances in the Knowledge and Clinical Applications of Lactic Acid Bacteria as Probiotics in the Urogenital Tract
Current Women`s Health Reviews SNPs of Metabolic Syndrome are Associated with Benign Prostatic Hyperplasia Development and Progression in Chinese Population
Current Bioinformatics Acylation Stimulating Protein and Triacylglycerol Synthesis: Potential Drug Targets?
Current Pharmaceutical Design Geriatric Evaluation of Oncological Elderly Patients
Anti-Cancer Agents in Medicinal Chemistry The miRNAs and Epithelial-Mesenchymal Transition in Cancers
Current Pharmaceutical Design Central G-Protein Coupled Receptors (GPCR)s as Molecular Targets for the Treatment of Obesity: Assets, Liabilities and Development Status
Current Drug Targets - CNS & Neurological Disorders Obesity: The Metabolic Disease, Advances on Drug Discovery and Natural Product Research
Current Topics in Medicinal Chemistry The Pro-Survival Function of Akt Kinase can be Overridden or Altered to Contribute to Induction of Apoptosis
Current Cancer Drug Targets Chronic Diseases and COVID-19: A Review
Endocrine, Metabolic & Immune Disorders - Drug Targets